Target Pair ◆ pdl1-vegf-a
PD-L1 × VEGF-ADRAFT
1 · Executive Snapshot
Active Assets: 6 ｜ Companies: 7 ｜ Events: 5
73
Opportunity ScoreWatch
≥80 Golden / 65–79 Watch / <65 Hold（dim 1–5 × weighted, gp-master methodology）
2 · Why This Pair
Axis clinically validated (atezolizumab+bevacizumab FDA-approved 1L HCC 2020) but no PD-L1×VEGF bispecific approved yet; lead asset BNT327/PM8002 (Biotheus→BioNTech→BMS) drives global Phase 3 programs — validates demand differences vs PD-1×VEGF architecture.
3 · Asset Landscape
- 01BNT327/PM8002 (pumitamig) — Biotheus→BioNTech→BMS, αPD-L1×αVEGF-A, global Ph3 (TNBC/NSCLC) + Ph2/3 Lung-02 (interim ORR ~70%)
- 02IMM2510/palverafusp alfa — ImmuneOnco, Ph2/3 endometrial (China)
- 03HB0025 — Huahai, 2× China Ph3 (NSCLC + endometrial; ASCO 2025 ORR 84.3% 1L endometrial)
- 04HLX37 — Henlius, Phase 1
- 05JSKN027 — Alphamab, PD-L1×VEGFR2 ADC (IND)
- 06(excluded: ivonescimab/AK112, LM-299 — PD-1×VEGF, not this pair)
4 · Companies
- 01Biotheus (origin)
- 02BioNTech (acquirer)
- 03BMS (global co-dev partner)
- 04ImmuneOnco
- 05Huahai/Huaotaibio
- 06Henlius
- 07Alphamab
5 · Clinical & Deal Events
| Date | Event | Company |
|---|---|---|
| 2020-05 | atezolizumab+bevacizumab FDA approval 1L HCC (axis validation, IMbrave150) | Roche |
| 2024-11 | BioNTech acquires PM8002 (Biotheus, $800M upfront / up to $950M) | BioNTech/Biotheus |
| 2025-06 | BMS global co-development deal (up to ~$11.1B) | BMS/BioNTech |
| 2025-11 | Instil Bio terminates ~$2B IMM2510 license (rights returned) | Instil Bio/ImmuneOnco |
| 2026 | Lung-02 interim ORR ~70% (sq 72.7%) presented | BioNTech, ASCO 2026 |
6 · Risks & Failures
- 01No PD-L1×VEGF bispecific approved yet (fast-follower position)
- 02Instil Bio terminated IMM2510 license (Nov 2025, rights returned)
- 03Combo-class failures: LEAP-002 / COSMIC-312 / IMmotion151 (PD-L1+anti-VEGF combinations)
- 04Anti-VEGF class AEs (bleeding, hypertension, proteinuria)
- 05BMS–BioNTech financial split conflicts (Grade C, excluded from core facts)
7 · Discovery Questions
- 01BNT327 pivotal PFS/OS + safety details (only interim ORR public)
- 02BMS–BioNTech economics / territorial split (Grade C conflicts)
- 03China-only program details (IMM2510 NMPA timing, HB0025 Ph3 designs)
- 04Differentiation of PD-L1×VEGF vs PD-1×VEGF architectures in the clinic
8 · Research Tools
- 01PD-L1 (CD274) ECD — mature formats (His/Avi/biotin)
- 02VEGF-A ECD (VEGFA) — mature formats
- 03Human/Cyno cross-species
- 04Dual-binding SPR/BLI panel (simultaneous engagement)
- 05Reference: bevacizumab-class anti-VEGF, atezolizumab-class anti-PD-L1
9 · Assay Workflow
Binding → Dual Binding → Functional (per PRD §20 §9).
10 · Services
11 · Evidence
Last reviewed: 2026-08-19 ｜ Confidence: medium ｜ Evidence: Score 73/100 = Watch (PRD §7); Grade A/B only; full ledger in gp-master (BMS/BioNTech financial split = Grade C, excluded)
Full evidence ledger: gp-master/GP-02_pdl1-vegf-a.md（本仓库 docs/artifacts/gp-master/，未托管外链）
Next steps